NCT04498182 - A Phase 2b Study Evaluating the Safety and Efficacy of AR-15512 Ophthalmic Solution for the Treatment of Dry Eye Disease | Biotech Hunter

Enrollment

369

Participants

Timeline

Start Date

October 26, 2020

Primary Completion Date

July 17, 2021

Study Completion Date

July 17, 2021

Conditions

Dry Eye Disease

Interventions

DRUG

AR-15512 Ophthalmic Solution

Ophthalmic solution administered via topical ocular instillation in one of two dose concentrations: 0.0014% (lower dose) or 0.003% (higher dose)

DRUG

AR-15512 Ophthalmic Solution Vehicle

Ophthalmic solution vehicle administered via topical ocular instillation

Trial Locations (15)

24502

Piedmont Eye Center, Lynchburg

28150

Vita Eye Clinic, Shelby

37167

Advancing Vision Research, LLC, Smyrna

38119

Total Eye Care, PA, Memphis

40206

The Eye Care Institute, Louisville

46240

Michael Washburn Center for Ophthalmic Research, LLC, Indianapolis

46290

Midwest Cornea Associates, LLC, Carmel

55340

Complete Eye Care of Medina, Hamel

64154

Moyes Eye Center, Kansas City

80907

Vision Institute, Colorado Springs

84015

Alpine Research Organization, Inc,, Clinton

85032

Cornea and Cataract Consultants of Arizona, Phoenix

92663

Eye Research Foundation, Newport Beach

01810

Andover Eye Associates, Andover

02767

Andover Eye Associates, Raynham